DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells

Wilberto Nieves-Neira, Maria I. Rivera, Glenda Kohlhagen, Miriam L. Hursey, Philippe Pourquier, Edward A. Sausville, Yves Pommier

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

2, 5-bis(5-Hydroxymethyl-2-thienyl)furan (NSC 652287), is a representative of a series of thiophene derivatives that exhibit potent and selective antitumor activity against several tumor cell lines in the National Cancer Institute Anticancer Drug Screen. NSC 652287 has noticeable activity for the renal cell lines and produces cures in certain corresponding xenografts. The cellular mechanisms of action of NSC 652287 were therefore investigated in this study in greater detail. The most sensitive renal carcinoma cell line, A498, exhibited cell cycle arrest in G0-G1 and G2-M at 10 nM NSC 652287, with increased p53 and p21(WAF1) protein. At higher concentrations, NSC 652287 still induced p53 elevation but with p21(WAF1) reduction and massive apoptosis. These results collectively suggested that NSC 652287 induced DNA damage. Using alkaline elution techniques, we found that NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. These DNA-protein cross-links (DPC) persisted for at least 12 h after drug removal and their frequency was correlated with cytotoxicity in the renal cell lines studied. The most sensitive cells (A498) produced the highest DPC followed by the cell line with intermediate sensitivity (TK-10). DPC were minimal in the two resistant cell lines, ACHN and UO-31. Nonetheless, a similar degree of DPC occurred at doses imparting equitoxic effects. These results indicate that DNA is a primary target for the novel and potent anticancer thiophene derivative, NSC 652287. NSC 652287 did not cross-Link purified DNA or mammalian topoisomerase I suggesting the importance of active metabolite(s) for the cross-linking activity.

Original languageEnglish (US)
Pages (from-to)478-484
Number of pages7
JournalMolecular Pharmacology
Volume56
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

NSC 652287
Thiophenes
Renal Cell Carcinoma
DNA
Cell Line
Kidney
link protein
Single-Stranded DNA Breaks
Type I DNA Topoisomerase
National Cancer Institute (U.S.)

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nieves-Neira, W., Rivera, M. I., Kohlhagen, G., Hursey, M. L., Pourquier, P., Sausville, E. A., & Pommier, Y. (1999). DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Molecular Pharmacology, 56(3), 478-484.

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. / Nieves-Neira, Wilberto; Rivera, Maria I.; Kohlhagen, Glenda; Hursey, Miriam L.; Pourquier, Philippe; Sausville, Edward A.; Pommier, Yves.

In: Molecular Pharmacology, Vol. 56, No. 3, 1999, p. 478-484.

Research output: Contribution to journalArticle

Nieves-Neira, W, Rivera, MI, Kohlhagen, G, Hursey, ML, Pourquier, P, Sausville, EA & Pommier, Y 1999, 'DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells', Molecular Pharmacology, vol. 56, no. 3, pp. 478-484.
Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Molecular Pharmacology. 1999;56(3):478-484.
Nieves-Neira, Wilberto ; Rivera, Maria I. ; Kohlhagen, Glenda ; Hursey, Miriam L. ; Pourquier, Philippe ; Sausville, Edward A. ; Pommier, Yves. / DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. In: Molecular Pharmacology. 1999 ; Vol. 56, No. 3. pp. 478-484.
@article{123353e0ef1d4e2ca651fb3e5f15398d,
title = "DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells",
abstract = "2, 5-bis(5-Hydroxymethyl-2-thienyl)furan (NSC 652287), is a representative of a series of thiophene derivatives that exhibit potent and selective antitumor activity against several tumor cell lines in the National Cancer Institute Anticancer Drug Screen. NSC 652287 has noticeable activity for the renal cell lines and produces cures in certain corresponding xenografts. The cellular mechanisms of action of NSC 652287 were therefore investigated in this study in greater detail. The most sensitive renal carcinoma cell line, A498, exhibited cell cycle arrest in G0-G1 and G2-M at 10 nM NSC 652287, with increased p53 and p21(WAF1) protein. At higher concentrations, NSC 652287 still induced p53 elevation but with p21(WAF1) reduction and massive apoptosis. These results collectively suggested that NSC 652287 induced DNA damage. Using alkaline elution techniques, we found that NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. These DNA-protein cross-links (DPC) persisted for at least 12 h after drug removal and their frequency was correlated with cytotoxicity in the renal cell lines studied. The most sensitive cells (A498) produced the highest DPC followed by the cell line with intermediate sensitivity (TK-10). DPC were minimal in the two resistant cell lines, ACHN and UO-31. Nonetheless, a similar degree of DPC occurred at doses imparting equitoxic effects. These results indicate that DNA is a primary target for the novel and potent anticancer thiophene derivative, NSC 652287. NSC 652287 did not cross-Link purified DNA or mammalian topoisomerase I suggesting the importance of active metabolite(s) for the cross-linking activity.",
author = "Wilberto Nieves-Neira and Rivera, {Maria I.} and Glenda Kohlhagen and Hursey, {Miriam L.} and Philippe Pourquier and Sausville, {Edward A.} and Yves Pommier",
year = "1999",
language = "English (US)",
volume = "56",
pages = "478--484",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells

AU - Nieves-Neira, Wilberto

AU - Rivera, Maria I.

AU - Kohlhagen, Glenda

AU - Hursey, Miriam L.

AU - Pourquier, Philippe

AU - Sausville, Edward A.

AU - Pommier, Yves

PY - 1999

Y1 - 1999

N2 - 2, 5-bis(5-Hydroxymethyl-2-thienyl)furan (NSC 652287), is a representative of a series of thiophene derivatives that exhibit potent and selective antitumor activity against several tumor cell lines in the National Cancer Institute Anticancer Drug Screen. NSC 652287 has noticeable activity for the renal cell lines and produces cures in certain corresponding xenografts. The cellular mechanisms of action of NSC 652287 were therefore investigated in this study in greater detail. The most sensitive renal carcinoma cell line, A498, exhibited cell cycle arrest in G0-G1 and G2-M at 10 nM NSC 652287, with increased p53 and p21(WAF1) protein. At higher concentrations, NSC 652287 still induced p53 elevation but with p21(WAF1) reduction and massive apoptosis. These results collectively suggested that NSC 652287 induced DNA damage. Using alkaline elution techniques, we found that NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. These DNA-protein cross-links (DPC) persisted for at least 12 h after drug removal and their frequency was correlated with cytotoxicity in the renal cell lines studied. The most sensitive cells (A498) produced the highest DPC followed by the cell line with intermediate sensitivity (TK-10). DPC were minimal in the two resistant cell lines, ACHN and UO-31. Nonetheless, a similar degree of DPC occurred at doses imparting equitoxic effects. These results indicate that DNA is a primary target for the novel and potent anticancer thiophene derivative, NSC 652287. NSC 652287 did not cross-Link purified DNA or mammalian topoisomerase I suggesting the importance of active metabolite(s) for the cross-linking activity.

AB - 2, 5-bis(5-Hydroxymethyl-2-thienyl)furan (NSC 652287), is a representative of a series of thiophene derivatives that exhibit potent and selective antitumor activity against several tumor cell lines in the National Cancer Institute Anticancer Drug Screen. NSC 652287 has noticeable activity for the renal cell lines and produces cures in certain corresponding xenografts. The cellular mechanisms of action of NSC 652287 were therefore investigated in this study in greater detail. The most sensitive renal carcinoma cell line, A498, exhibited cell cycle arrest in G0-G1 and G2-M at 10 nM NSC 652287, with increased p53 and p21(WAF1) protein. At higher concentrations, NSC 652287 still induced p53 elevation but with p21(WAF1) reduction and massive apoptosis. These results collectively suggested that NSC 652287 induced DNA damage. Using alkaline elution techniques, we found that NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. These DNA-protein cross-links (DPC) persisted for at least 12 h after drug removal and their frequency was correlated with cytotoxicity in the renal cell lines studied. The most sensitive cells (A498) produced the highest DPC followed by the cell line with intermediate sensitivity (TK-10). DPC were minimal in the two resistant cell lines, ACHN and UO-31. Nonetheless, a similar degree of DPC occurred at doses imparting equitoxic effects. These results indicate that DNA is a primary target for the novel and potent anticancer thiophene derivative, NSC 652287. NSC 652287 did not cross-Link purified DNA or mammalian topoisomerase I suggesting the importance of active metabolite(s) for the cross-linking activity.

UR - http://www.scopus.com/inward/record.url?scp=0032838772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032838772&partnerID=8YFLogxK

M3 - Article

C2 - 10462535

AN - SCOPUS:0032838772

VL - 56

SP - 478

EP - 484

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -